The American Society for Clinical Oncology annual meeting never fails to deliver inspiring advances in cancer-care.
In theory, in vivo makes other cell therapies obsolete, but a panel at BPI Europe in Vienna last month painted a more measured picture.
Here are 10 best practices that can help drug developers avoid delays, protect data quality, and meet regulatory, clinical and manufacturing expectations.
Developers who treat China’s rise as a strategic opportunity — both for partnership and as a wakeup call to address inefficiencies in Western systems — will be best positioned to take home the ultimate prize: bringing lifesaving treatments to more patients.
Robust CCI verification is essential not only for regulatory compliance but also for protecting product stability and patient safety. As advanced therapies become more complex, the rigor and precision of CCI testing will remain indispensable.
Wednesday, April 29, 2026
The cell therapy sector remains constrained by particulate guidance based on traditional parenteral products, says a BioPhorum publication.
Wednesday, April 15, 2026
Cultivating resilient, stage-appropriate supply strategies is an essential yet often overlooked part of delivering safe, effective therapies to patients.
Wednesday, April 01, 2026
New findings establish the feasibility of combining nonviral ex vivo gene editing, hepatocyte transplantation, and in vivo selection, and support the clinical translation of cell-based gene-editing therapies for inherited metabolic liver diseases.
Wednesday, March 25, 2026
We are living in the golden age of cell and gene therapy — but the spoils will go to those who chart a deliberate course, choose the right partners, and translate breakthrough science into sustainable commercial reality.
A well-designed development roadmap can be a powerful strategic asset — shaping investor confidence and guiding capital deployment. Yet questions persist around the optimal timing for roadmap buildout and how it should evolve alongside preclinical development activities and fundraising efforts.